Corpus Intelligence IC Memo — TEMPE ST. LUKES HOSPITAL 2026-04-26 15:53 UTC
IC Memo — TEMPE ST. LUKES HOSPITAL
Investment Committee Memorandum | AZ | 74 beds | Grade D | EBITDA uplift $5.6M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

TEMPE ST. LUKES HOSPITAL

CCN 030037 | MARICOPA, AZ | 74 beds | April 26, 2026
EBITDA BridgeData Room
D
Investability

1. Target Overview & Investment Thesis

TEMPE ST. LUKES HOSPITAL is a 74-bed suburban community hospital in MARICOPA, AZ with $75.8M in net patient revenue and a 3.6% operating margin. The hospital serves a payer mix of 10.4% Medicare, 6.6% Medicaid, and 83.0% commercial.

Thesis: Turnaround. Our ML models identify $5.6M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 3.6% to 11.0% (+736bps).

Net Revenue HCRIS$75.8M
Current EBITDA COMPUTED$2.8M
Operating Margin COMPUTED3.6%
Occupancy HCRIS32.3%
Revenue / Bed COMPUTED$1.0M
Net-to-Gross HCRIS21.3%
Distress Probability ML51.3%

2. Market Context & Competitive Position

124
AZ Hospitals
-0.8%
State Median Margin
54
Comparable Hospitals

AZ has 124 Medicare-certified hospitals with a median operating margin of -0.8%. The target's margin of 3.6% places it above the state median. Among 54 size-comparable peers (37-148 beds), the median margin is 2.2%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (37-148), prioritizing same-state peers. 54 hospitals in the comp set.

HospitalStateBedsRevenueMargin
TEMPE ST. LUKES HOSPITAL (Target)AZ74$75.8M3.6%
HAVASU REGIONAL MEDICAL CENTERAZ144$256.1M16.9%
SUMMIT HEALTHCAREAZ89$254.1M-2.9%
BANNER UNIVERSITY MED CENTER SAZ132$190.9M-16.3%
HONORHEALTH SCOTTSDALE THOMPSOAZ120$187.9M-1.6%
VERDE VALLEY MEDICAL CENTERAZ87$172.5M4.3%
BANNER HEART HOSPITALAZ108$162.2M17.4%
BANNER CASA GRANDE MEDICAL CENAZ141$151.2M-6.3%
NORTHWEST MEDICAL CENTER ORO VAZ96$145.8M10.6%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $5.6M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$1.6M+210bp18mo
Cost to Collect4.5%2.5%$1.5M+200bp12mo
Denial Rate Reduction12.0%6.5%$1.5M+198bp12mo
A/R Days Reduction5200.0%3800.0%$923K+122bp9mo
Clean Claim Rate88.0%96.0%$49K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$1.6M
Cost to Collect
$1.5M
Denial Rate Reduction
$1.5M
A/R Days Reduction
$923K
Clean Claim Rate
$49K
Total EBITDA Uplift$5.6M
Current EBITDA$2.8M
+ RCM Uplift+$5.6M
Pro Forma EBITDA$8.3M
Current Margin3.6%
Pro Forma Margin11.0%
WC Released (1x)$2.9M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$4.2M$74.0M17.45x77.2%
Base (11x exit)10.0x11.0x$4.2M$82.8M19.52x81.2%
Bull Case9.0x11.0x$3.8M$102.6M26.88x93.1%
Bull (12x exit)9.0x12.0x$3.8M$113.0M29.62x96.9%
Bear Case11.0x10.0x$4.7M$44.7M9.59x57.2%
Bear (11x exit)11.0x11.0x$4.7M$50.7M10.87x61.2%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumLow occupancyAt 32.3%, fixed costs are spread over fewer patient days. Mitigant: volume growth is an additional upside lever not modeled in base case
HighElevated distress probabilityModel estimates 51.3% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 54 hospitals with 37-148 beds
  • Same-state prioritization (n=55)
  • Comp margins: P25=-10.9% / P50=2.2% / P75=10.2%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.